Studies using sialidase inhibitors like 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA) and animal models with Neu-1 knockout or overexpression show that inhibiting Neu-1 leads to hyperglycemia and impaired glucose tolerance [31,33]. Here, NEU1 is linked to Hyperglycemia.